Biofrontera AG

5.50+0.0500+0.92%Vol 6.29K1Y Perf -15.38%
Apr 23rd, 2021 10:20 DELAYED
BID5.46 ASK5.57
Open5.51 Previous Close5.45
Pre-Market- After-Market-
 - -%  - -
Target Price
13.00 
Analyst Rating
Moderate Buy 2.00
Potential %
136.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     43.08
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     44.84
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap155.97M 
Earnings Rating
Neutral
Price Range Ratio 52W %
1.65 
Earnings Date
18th May 2021

Today's Price Range

5.475.55

52W Range

4.6755.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.49%
1 Month
-5.55%
3 Months
-31.88%
6 Months
-26.65%
1 Year
-15.38%
3 Years
-61.35%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BFRA5.500.05000.92
AAPL133.561.62001.23
GOOG2 293.3225.40001.12
MSFT259.161.99000.77
XOM55.730.46000.83
WFC43.610.91002.13
JNJ165.610.43000.26
FB298.431.91000.64
GE13.580.17001.27
JPM149.692.32001.57
Financial StrengthValueIndustryS&P 500US Markets
2.50
3.20
0.76
3.24
-3.10
Leverage Ratio 8.90
ProfitabilityValueIndustryS&P 500US Markets
88.40
-35.50
-35.50
-91.00
-31.52
RevenueValueIndustryS&P 500US Markets
29.66M
1.05
30.94
55.40
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.28-
Q02 2020-0.04-
Q01 2020--0.31-
Q04 2019--0.22-
Q03 2019--0.59-
Q02 2019-0.58-
Q01 2019--0.14-
Q04 2018--0.18-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date18th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume6.29K
Shares Outstanding28.36M
Trades Count58
Dollar Volume778.61K
Avg. Volume72.90K
Avg. Weekly Volume22.41K
Avg. Monthly Volume46.26K
Avg. Quarterly Volume63.60K

Biofrontera AG (NASDAQ: BFRA) stock closed at 5.45 per share at the end of the most recent trading day (a -0.91% change compared to the prior day closing price) with a volume of 13.12K shares and market capitalization of 155.97M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 155 people. Biofrontera AG CEO is Hermann Lubbert.

The one-year performance of Biofrontera AG stock is -15.38%, while year-to-date (YTD) performance is -25.24%. BFRA stock has a five-year performance of %. Its 52-week range is between 4.67 and 55, which gives BFRA stock a 52-week price range ratio of 1.65%

Biofrontera AG currently has a PE ratio of -9.80, a price-to-book (PB) ratio of 17.76, a price-to-sale (PS) ratio of 5.26, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.70%, a ROC of -41.45% and a ROE of -150.30%. The company’s profit margin is -31.52%, its EBITDA margin is -35.50%, and its revenue ttm is $29.66 Million , which makes it $1.05 revenue per share.

Of the last four earnings reports from Biofrontera AG, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Biofrontera AG’s next earnings report date is 18th May 2021.

The consensus rating of Wall Street analysts for Biofrontera AG is Moderate Buy (2), with a target price of $13, which is +136.36% compared to the current price. The earnings rating for Biofrontera AG stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biofrontera AG has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biofrontera AG has a Sell technical analysis rating based on Technical Indicators (ADX : 22.91, ATR14 : 0.41, CCI20 : -30.14, Chaikin Money Flow : -0.32, MACD : -0.54, Money Flow Index : 29.74, ROC : -6.68, RSI : 37.68, STOCH (14,3) : 31.25, STOCH RSI : 0.90, UO : 37.83, Williams %R : -68.75), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biofrontera AG in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (50.00 %)
1 (50.00 %)
1 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
2.00
Moderate Buy
2.00

Biofrontera AG

Biofrontera AG is active in the field of healthcare in the United Kingdom. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

CEO: Hermann Lubbert

Telephone: +49 2148733200

Address: Hemmelrather Weg 201, Leverkusen D-51377, , DE

Number of employees: 155

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

News

Stocktwits